ECSP034743A - Peptidos a partir del anticuerpo 16/61d para tratar lupus eritematoso sistemico - Google Patents

Peptidos a partir del anticuerpo 16/61d para tratar lupus eritematoso sistemico

Info

Publication number
ECSP034743A
ECSP034743A EC2003004743A ECSP034743A ECSP034743A EC SP034743 A ECSP034743 A EC SP034743A EC 2003004743 A EC2003004743 A EC 2003004743A EC SP034743 A ECSP034743 A EC SP034743A EC SP034743 A ECSP034743 A EC SP034743A
Authority
EC
Ecuador
Prior art keywords
peptides
antibody
erythemate
lupus
treat systemic
Prior art date
Application number
EC2003004743A
Other languages
English (en)
Inventor
Edna Mozes
Original Assignee
Yeda Reserach And Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Reserach And Dev Co Ltd filed Critical Yeda Reserach And Dev Co Ltd
Publication of ECSP034743A publication Critical patent/ECSP034743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Péptidos sintéticos de al menos 12 y de máximo 30 residuos de aminoácidos que comprenden una secuencia que consiste de, o que se encuentra en, una región determinante complementaridad (CDR) encontrada en la cadena pesada o en cadena ligera del anticuerpo monoclonal 16/6ld anti-ADN de humano, o una secuencia obtenida mediante el reemplazo y/o la deleción y/o la adición de uno o más residuos de aminoácidos a dicha secuencia, y sales, derivados químicos y polímeros de dichos peptidos que pueden ser utilizados para la inmunomodulación de las respuestas asociadas con el lups sistémico eritematoso.
EC2003004743A 2001-02-26 2003-08-22 Peptidos a partir del anticuerpo 16/61d para tratar lupus eritematoso sistemico ECSP034743A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14164701A IL141647A0 (en) 2001-02-26 2001-02-26 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
ECSP034743A true ECSP034743A (es) 2004-01-28

Family

ID=11075174

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004743A ECSP034743A (es) 2001-02-26 2003-08-22 Peptidos a partir del anticuerpo 16/61d para tratar lupus eritematoso sistemico

Country Status (28)

Country Link
US (2) US20040127408A1 (es)
EP (1) EP1370575B1 (es)
JP (1) JP4316886B2 (es)
KR (1) KR100860735B1 (es)
CN (1) CN1309733C (es)
AT (1) ATE346094T1 (es)
AU (1) AU2002233618B2 (es)
BR (1) BR0207586A (es)
CA (1) CA2439051C (es)
CR (1) CR7058A (es)
CU (1) CU23276B7 (es)
DE (1) DE60216243T2 (es)
DK (1) DK1370575T3 (es)
EA (1) EA009465B1 (es)
EC (1) ECSP034743A (es)
ES (1) ES2275832T3 (es)
HR (1) HRP20030667A2 (es)
HU (1) HU230372B1 (es)
IL (3) IL141647A0 (es)
IS (1) IS6908A (es)
MX (1) MXPA03007622A (es)
NO (1) NO331820B1 (es)
NZ (1) NZ527499A (es)
PL (1) PL373520A1 (es)
PT (1) PT1370575E (es)
SI (1) SI1370575T1 (es)
WO (1) WO2002067848A2 (es)
ZA (1) ZA200305874B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753135B2 (en) * 2000-09-20 2004-06-22 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
UA83816C2 (ru) * 2003-01-14 2008-08-26 Тева Фармасьютикал Индастриз, Лтд ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ
US20050008634A1 (en) * 2003-01-14 2005-01-13 Sharon Cohen-Vered Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8313950B2 (en) * 2007-05-21 2012-11-20 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
WO2015051330A1 (en) 2013-10-03 2015-04-09 Oregon Health & Science University RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II α1 DOMAINS
AU2018205885A1 (en) * 2017-01-05 2019-06-27 Yeda Research And Development Co. Ltd. Peptides for treating Sjogren's syndrome
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用
KR20260033046A (ko) * 2023-07-03 2026-03-10 단 골드스타우브 전신성 홍반성 루푸스의 치료를 위한 조성물 및 방법
WO2025027013A1 (en) * 2023-08-01 2025-02-06 Diamante Srl Composition and methods for treating system lupus erythematosus

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127408A (en) * 1872-06-04 Improvement in tooth-powders or dentifrices
US8634A (en) * 1852-01-06 Wool-pickina machine
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
EP1045836B1 (en) * 1997-12-18 2008-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Pyridones as src family sh2 domain inhibitors
KR100261262B1 (ko) * 1998-02-03 2000-08-01 윤종용 반도체 습식 설비의 구조 및 이의 로트 로딩/언로딩 방법
US6415877B1 (en) * 1998-07-15 2002-07-09 Deep Vision Llc Subsea wellbore drilling system for reducing bottom hole pressure
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US20050008634A1 (en) * 2003-01-14 2005-01-13 Sharon Cohen-Vered Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
UA83816C2 (ru) 2003-01-14 2008-08-26 Тева Фармасьютикал Индастриз, Лтд ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ

Also Published As

Publication number Publication date
EP1370575A4 (en) 2004-09-29
JP4316886B2 (ja) 2009-08-19
HRP20030667A2 (en) 2005-06-30
JP2005505493A (ja) 2005-02-24
CU23276B7 (es) 2008-04-09
HUP0600778A2 (en) 2007-01-29
CA2439051A1 (en) 2002-09-06
DK1370575T3 (da) 2007-01-29
US20040127408A1 (en) 2004-07-01
DE60216243T2 (de) 2007-10-31
IL157550A (en) 2010-05-31
IL157550A0 (en) 2004-03-28
AU2002233618B2 (en) 2006-12-21
BR0207586A (pt) 2006-11-07
WO2002067848A3 (en) 2002-12-12
CN1309733C (zh) 2007-04-11
NO20033718D0 (no) 2003-08-21
WO2002067848A2 (en) 2002-09-06
HU230372B1 (hu) 2016-03-29
IL141647A0 (en) 2002-03-10
ATE346094T1 (de) 2006-12-15
SI1370575T1 (sl) 2007-04-30
NO331820B1 (no) 2012-04-10
US20080119390A1 (en) 2008-05-22
MXPA03007622A (es) 2004-09-14
HUP0600778A3 (en) 2012-09-28
EP1370575A2 (en) 2003-12-17
US7858738B2 (en) 2010-12-28
PL373520A1 (en) 2005-09-05
NO20033718L (no) 2003-10-09
ES2275832T3 (es) 2007-06-16
CR7058A (es) 2004-11-01
EP1370575B1 (en) 2006-11-22
IS6908A (is) 2003-08-11
DE60216243D1 (de) 2007-01-04
KR100860735B1 (ko) 2008-09-29
HK1059790A1 (en) 2004-07-16
CN1503806A (zh) 2004-06-09
PT1370575E (pt) 2007-01-31
EA200300939A1 (ru) 2004-12-30
CA2439051C (en) 2010-02-02
EA009465B1 (ru) 2007-12-28
ZA200305874B (en) 2005-08-31
KR20030092004A (ko) 2003-12-03
NZ527499A (en) 2005-12-23

Similar Documents

Publication Publication Date Title
ECSP034743A (es) Peptidos a partir del anticuerpo 16/61d para tratar lupus eritematoso sistemico
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
CR6425A (es) Anticuerpos monoclonales humanos de ctla-4
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
BRPI0410031A (pt) variantes fc otimizadas e métodos para sua geração
CY1117617T1 (el) Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας
EA200401169A1 (ru) Аминометилзамещенные тетрациклиновые соединения
PE20091205A1 (es) Anticuerpo anti-receptor de il-6
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
EA200201214A1 (ru) Замещенные тиоацетамиды
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1113312T1 (el) Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
DE60135330D1 (de) Reinigung von xanthophyllen aus ringelblumenextrakten mit hohem chlorophyllgehalt
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
CY1109207T1 (el) Διαδικασια εχινοκανδινης
PE20061444A1 (es) Anticuerpo anti-mcp-1, composiciones, metodos y usos
EA200500878A1 (ru) Кальцилитические соединения
ES2185652T3 (es) Oligopeptidos derivados de fragmentos de proteinas c-reactiva.
EA200200798A1 (ru) Кальцилитические соединения
NO20030684L (no) valiteten i produkter, samt et proteinhydrolysat fFremgangsmater for a forbedre egenskaper av kjottkremstilt av et fiskemateriale
SE7713700L (sv) 2-substituerade-1-(omega-aminoalkoxi)bensener
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
WO2006023211A3 (en) Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof